iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares

Key Points

• CEO Roger Susi sold 5,000 shares on April 6 under a pre-arranged Rule 10b5-1 plan at an average price of $96.02 for $480,100, leaving him with 2,220,000 shares (a 0.22% reduction) valued at about $213.16M.
• iRadimed beat Q4 expectations with $0.54 EPS and $22.69M revenue, issued Q1 2026 guidance of 0.440–0.480 EPS and FY2026 guidance of 2.060–2.210 EPS, and increased its quarterly dividend to $0.20 from $0.17.
• Shares traded down ~2.4% to $93.39 (market cap ~$1.19B, P/E ~53.4), and analysts maintain a consensus Buy rating with an average target price of $120.00.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $96.02, for a total transaction of $480,100.00. Following the transaction, the chief executive officer owned 2,220,000 shares of the company's stock, valued at $213,164,400. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Trading Down 2.4%

NASDAQ:IRMD traded down $2.27 during trading hours on Tuesday, reaching $93.39. 75,223 shares of the company were exchanged, compared to its average volume of 75,773. The stock's 50-day moving average is $99.63 and its 200-day moving average is $91.74. The firm has a market cap of $1.19 billion, a PE ratio of 53.37 and a beta of 1.11. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million during the quarter, compared to analysts' expectations of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, research analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were given a dividend of $0.20 per share. This is a boost from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Monday, February 23rd. iRadimed's dividend payout ratio (DPR) is currently 45.71%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IRMD. Freedom Capital upgraded shares of iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. Weiss Ratings reiterated a "buy (b-)" rating on shares of iRadimed in a research report on Monday, December 29th. Lake Street Capital reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Roth Mkm reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $120.00.

Institutional Investors Weigh In On iRadimed

A number of hedge funds have recently modified their holdings of IRMD. CWM LLC grew its holdings in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 211 shares during the period. Quarry LP purchased a new position in iRadimed during the third quarter worth about $40,000. Farther Finance Advisors LLC boosted its stake in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $43,000 after buying an additional 397 shares during the period. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after buying an additional 495 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in iRadimed during the third quarter worth about $47,000. Hedge funds and other institutional investors own 92.34% of the company's stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.